

AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended): An isolated, modified anti-viral peptide-albumin conjugate comprising: consisting of: an anti-viral peptide comprising a that has been modified to contain a succinimidyl or maleimide containing group and an amino acid sequence, wherein said which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds, said peptide consisting of an amino acid sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, wherein said sequence exhibits[[ing]] an anti-viral activity against human immunodeficiency virus (HIV) wherein and said isolated peptide is covalently bonded to cysteine 34 of albumin through said maleimide containing group to form said peptide-albumin conjugate wherein the ratio of peptide to albumin in said conjugate is 1:1 a blood component.

Claim 2 (canceled).

Claim 3 (canceled).

Claim 4 (currently amended): The isolated, modified anti-viral peptide-albumin conjugate of claim 1 wherein said peptide is DP 178, the amino acid sequence of which is SEQ ID NO:1.

Claim 5 (canceled).

Claim 6 (currently amended): The isolated, modified anti-viral peptide-albumin conjugate of claim 1 wherein said peptide has an amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claims 7-18 (canceled).

Claim 19 (currently amended): A composition for use in the ~~prevention and/or treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically acceptable medium, an anti-viral modified peptide-albumin conjugate comprising consisting of an anti-viral peptide that has been modified to contain a succinimidyl or comprising a maleimide containing group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds, said peptide consisting of and an amino acid sequence wherein said sequence is~~ selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, wherein said sequence exhibits[[ing]] an anti-viral activity against human immunodeficiency virus (HIV) wherein and said peptide is covalently bonded to cysteine 34 of albumin through said maleimide containing group to form said anti-viral peptide-albumin conjugate, wherein the ratio of peptide to albumin in said conjugate is 1:1 a blood component.

Claim 20 (canceled).

Claim 21 (currently amended): The composition of claim [[20]]19 wherein said peptide is DP 178, the amino acid sequence of which is SEQ ID NO:1.

Claims 22-30 (canceled).

Claim 31 (currently amended): The composition of claim 19 wherein said peptide has an amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claims 32-35 (canceled).

Claim 36 (currently amended): A composition comprising the ~~modified~~-anti-viral peptide-albumin conjugate of claim 1 in a physiologically acceptable medium.

Claim 37 (canceled).

Claim 38 (currently amended): The composition of claim 36 wherein said ~~modified~~ anti-viral peptide has the amino acid sequence is[[of]] SEQ ID NO:1.

Claim 39 (currently amended): The composition of claim 36 wherein said ~~modified~~ anti-viral peptide has an amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claims 40-58 (Canceled).

Please add the following new claims:

Claim 59 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said albumin is in blood.

Claim 60 (new) The anti-viral peptide-albumin conjugate of claim 59 wherein said blood is in a human.

Claim 61 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 3.

Claim 62 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 4.

Claim 63 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 5.

Claim 64 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 117.

Claim 65 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 118.

Claim 66 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 119.

Claim 67 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 534.

Claim 68 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 535.

Claim 69 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 536.

Claim 70 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 537.

Claim 71 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 538.

Claim 72 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 539.

Claim 73 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 540.

Claim 74 (new) The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 541.

Claim 75 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 3.

Claim 76 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 4.

Claim 77 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 5.

Claim 78 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 117.

Claim 79 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 118.

Claim 80 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 119.

Claim 81 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 534.

Claim 82 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 535.

Claim 83 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 536.

Claim 84 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 537.

Claim 85 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 538.

Claim 86 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 539.

Claim 87 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 540.

Claim 88 (new) The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 541.